Drug Profile
Conjugated estrogens - Pfizer
Alternative Names: PremarinLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Estradiol congeners; Hormonal replacements; Osteoporosis therapies
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Atrophic vaginitis; Dyspareunia; Postmenopausal osteoporosis; Primary ovarian insufficiency; Vasomotor symptoms
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Alzheimer's-disease(Prevention) in USA (PO, Tablet)
- 14 Jan 2014 Launched for Postmenopausal osteoporosis (prevention) in World (PO)
- 14 Jan 2014 Launched for Vasomotor symptoms in World (PO)